Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action
- 1 November 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 63 (11), 1217-23
- https://doi.org/10.1001/archpsyc.63.11.1217
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are often described as having a delayed onset of effect in the treatment of depression. However, some trials have reported clinical improvement as early as the first week of treatment. To test the alternative hypotheses of delayed vs early onset of antidepressant action with SSRIs in patients with unipolar depression. Trials identified by searching CENTRAL, The Cochrane Collaboration database of controlled trials (2005), and the reference lists of identified trials and other systematic reviews. Randomized controlled trials of SSRIs vs placebo for the treatment of unipolar depression in adults that reported outcomes for at least 2 time points in the first 4 weeks of treatment (50 trials from >500 citations identified). Trials were excluded if limited to participants older than 65 years or specific comorbidities. Data were extracted on trial design, participant characteristics, and outcomes by a single reviewer. Pooled estimates of treatment effect on depressive symptom rating scales were calculated for weeks 1 through 6 of treatment. In the primary analysis, the pattern of response seen was tested against alternative models of onset of response. The primary analysis incorporated data from 28 randomized controlled trials (n=5872). A model of early treatment response best fit the experimental data. Treatment with SSRIs rather than placebo was associated with clinical improvement by the end of the first week of use. A secondary analysis indicated an increased chance of achieving a 50% reduction in Hamilton Depression Rating Scale scores by 1 week (relative risk, 1.64; 95% confidence interval, 1.2-2.25) with SSRI treatment compared with placebo. Treatment with SSRIs is associated with symptomatic improvement in depression by the end of the first week of use, and the improvement continues at a decreasing rate for at least 6 weeks.Keywords
This publication has 64 references indexed in Scilit:
- Depression: a case of neuronal life and death?Biological Psychiatry, 2004
- Increased Positive Versus Negative Affective Perception and Memory in Healthy Volunteers Following Selective Serotonin and Norepinephrine Reuptake InhibitionAmerican Journal of Psychiatry, 2004
- Normalization of Enhanced Fear Recognition by Acute SSRI Treatment in Subjects With a Previous History of DepressionAmerican Journal of Psychiatry, 2004
- Development of the Cochrane Collaboration’s Central Register of Controlled Clinical TrialsEvaluation & the Health Professions, 2002
- CorrespondenceNeuropsychopharmacology, 1997
- Current advances and trends in the treatment of depressionTrends in Pharmacological Sciences, 1994
- A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholiaInternational Clinical Psychopharmacology, 1993
- Sixteen S‐squared over D‐squared: A relation for crude sample size estimatesStatistics in Medicine, 1992
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960